Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan versus dobutamine in acute heart failure requiring intravenous inotropic support
2004-001225-16Phase 3Completed
- Sponsor
- Orion Corporation
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) and acute decompensated heart failure (ADHF) comparing Levosimendan arm with Dobutamine arm (2 arms). Primary endpoint: All-cause mortality at 180 days. Started Sep 2004; status: completed.
02
Drugs
levosimendandobutamine
03
Conditions
Acute Heart Failure (AHF)acute decompensated heart failure (ADHF)
Beyond the preview
Go deeper on 2004-001225-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001225-16.